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Background
A major challenge for an HIV vaccine is to elicit potent
and broad neutralizing antibody (Nab) responses that
protect against diverse viruses. However, the nature and
location of available targets on the envelope (Env) glyco-
proteins of each incoming virus remain largely undefined.
Furthermore, should a vaccine elicit Nab, there has been
little consideration of how to prevent viral escape.
Methods
Here we characterized autologous Nab and viral escape
over the first two years of infection in 2 subtype C HIV-1
infected subjects in a Zambian cohort. Viral env genes
were cloned through SGA and Nab resistant variants were
identified at each time point using a pseudovirus-based
neutralization assay. These variants were then used to cre-
ate a series of Env chimeras and mutants within the back-
ground of the corresponding newly transmitted Env.
Monoclonal antibodies (Mabs) were derived from one
patient by EBV transformation of B cells to generate hybri-
domas.
Results
Escape from early Nab was driven by substitutions in the
V5 region in one subject, but an accompanying change in
the a2 helix did not contribute directly. Nab resistance at
later time points fluctuated between different molecular
pathways and at times required cooperative interactions
between gp41 and gp120. In contrast, V1V2 was the major
determinant of escape in the second subject at all time
points, and two Mabs derived from this patient targeted
this domain. Escape from the Mabs required changes in
two sites of potential N-linked glycosylation in V1 and V2
and the data suggests that escape from one Mab occurred
within 48 days of infection.
Conclusion
The findings provide strong evidence that the immuno-
genicity and perhaps exposure of the hyper-variable
domains on the transmitted Env launch the initial Nab
response, arguing that immunization strategies will need
to circumvent these defenses, or target them directly, to
induce a protective Nab response.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P125 doi:10.1186/1742-4690-6-S3-P125
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P125
© 2009 Rong et al; licensee BioMed Central Ltd. 